• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Agios Pharmaceuticals Inc.

    10/8/25 4:01:36 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AGIO alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001707715
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    AGIOS PHARMACEUTICALS, INC.
    SEC File Number
    001-36014
    Address of Issuer
    88 Sidney St.
    Cambridge
    MASSACHUSETTS
    02139
    Phone
    617-649-8600
    Name of Person for Whose Account the Securities are To Be Sold
    DAVID SCADDEN
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Director

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Morgan Stanley Smith Barney LLC Executive Financial Services
    1 New York Plaza
    8th Floor
    New York � NY � 10004
    2008200.005810151810/08/2025
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common10/08/2025Stock Option ExerciseIssuerCheckbox not checked20010/08/2025Cash

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    DAVID SCADDEN
    88 Sidney St.
    Cambridge � MA � 02139
    Common09/30/20252008000.00
    DAVID SCADDEN
    88 Sidney St.
    Cambridge � MA � 02139
    Common08/27/20252008000.00
    DAVID SCADDEN
    88 Sidney St.
    Cambridge � MA � 02139
    Common07/10/2025140056000.00

    144: Remarks and Signature

    Remarks
    Date of Notice
    10/08/2025
    Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1
    09/06/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ David Scadden

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $AGIO alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AGIO

    DatePrice TargetRatingAnalyst
    11/20/2025$34.00Market Perform → Outperform
    Leerink Partners
    11/19/2025$28.00Outperform → Sector Perform
    RBC Capital Mkts
    2/24/2025$58.00Buy
    H.C. Wainwright
    10/16/2024Sector Outperform
    Scotiabank
    10/10/2024$51.00Outperform
    Raymond James
    9/27/2024$60.00 → $56.00Outperform → Market Perform
    Leerink Partners
    2/8/2024Overweight
    Cantor Fitzgerald
    2/3/2023$41.00Overweight
    Piper Sandler
    More analyst ratings

    $AGIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Scadden David exercised 200 shares at a strike of $18.09 and sold $8,768 worth of shares (200 units at $43.84) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/14/25 4:04:55 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Gheuens Sarah exercised 2,454 shares at a strike of $25.01 and sold $107,436 worth of shares (2,454 units at $43.78) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/13/25 4:08:59 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Gheuens Sarah exercised 200 shares at a strike of $25.01 and sold $8,762 worth of shares (200 units at $43.81) (SEC Form 4)

    4 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Issuer)

    11/3/25 4:10:51 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for PYRUKYND issued to AGIOS PHARMACEUTICALS INC

    Submission status for AGIOS PHARMACEUTICALS INC's drug PYRUKYND (ORIG-1) with active ingredient MITAPIVAT has changed to 'Approval' on 02/17/2022. Application Category: NDA, Application Number: 216196, Application Classification: Type 1 - New Molecular Entity

    2/17/22 2:39:08 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for TIBSOVO issued to AGIOS PHARMS INC

    Submission status for AGIOS PHARMS INC's drug TIBSOVO (SUPPL-7) with active ingredient IVOSIDENIB has changed to 'Approval' on 03/18/2021. Application Category: NDA, Application Number: 211192, Application Classification: Labeling

    3/22/21 5:06:31 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    SEC Filings

    View All

    SEC Form 10-Q filed by Agios Pharmaceuticals Inc.

    10-Q - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    10/30/25 9:57:01 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AGIOS PHARMACEUTICALS, INC. (0001439222) (Filer)

    10/30/25 6:32:30 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Agios Pharmaceuticals Inc.

    144 - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    10/8/25 4:01:36 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Agios Pharma upgraded by Leerink Partners with a new price target

    Leerink Partners upgraded Agios Pharma from Market Perform to Outperform and set a new price target of $34.00

    11/20/25 7:56:46 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Pharma downgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts downgraded Agios Pharma from Outperform to Sector Perform and set a new price target of $28.00

    11/19/25 12:52:13 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Agios Pharma with a new price target

    H.C. Wainwright initiated coverage of Agios Pharma with a rating of Buy and set a new price target of $58.00

    2/24/25 7:01:42 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

    Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpoints and PROMIS Fatigue Favorable safety profile observed in RISE UP Phase 3 trial was consistent with that observed in prior mitapivat sickle cell disease trials Company will share the comprehens

    11/19/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

    $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused

    10/30/25 6:30:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avanzanite Bioscience's Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia

    Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP's opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on del

    10/17/25 8:15:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Leadership Updates

    Live Leadership Updates

    View All

    Agios Appoints Dr. Jay Backstrom to Board of Directors

    CAMBRIDGE, Mass., July 08, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in cellular metabolism and pyruvate kinase (PK) activation pioneering therapies for rare diseases, today announced the appointment of Jay Backstrom, M.D., M.P.H., to its Board of Directors, effective immediately. Dr. Backstrom is an accomplished healthcare executive with a proven track record of advancing clinical programs across a range of therapeutic areas, including rare diseases, to regulatory approval. "We are thrilled to welcome Jay to the Agios Board of Directors," said Brian Goff, Chief Executive Officer, Agios. "His deep scientific insight, extensive regulatory expertise, and s

    7/8/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cardurion Pharmaceuticals Appoints Charlotte Newman as Chief Business Officer

    Cardurion Pharmaceuticals, Inc. ("Cardurion"), a clinical-stage biotechnology company discovering and developing new therapeutic approaches for the treatment of cardiovascular diseases, today announced that Charlotte (Charlie) Newman has joined the company as Chief Business Officer. A biopharmaceutical industry executive with over 25 years of industry experience, Ms. Newman most recently led corporate, portfolio and program strategy and business development as Chief Business Officer of Agios Pharmaceuticals (NASDAQ:AGIO), and previously held strategic product and portfolio roles at Biogen (NASDAQ:BIIB). In her role at Cardurion, she will be responsible for leading corporate development, bus

    1/8/25 8:00:00 AM ET
    $AGIO
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Agios Appoints Catherine Owen to Board of Directors

    – John Maraganore Completes Tenure on Agios Board After Nearly a Dozen Years of Service – – Kaye Foster to Be Appointed Lead Independent Director – CAMBRIDGE, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that Catherine Owen has been appointed to its board of directors, effective June 13, 2023. Agios also announced that, following a collaborative succession planning process, John Maraganore, Ph.D., who has served as a valuable board member and advisor to the company since 2011, will step down from the board of directors, effective immediately, and

    5/25/23 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Financials

    Live finance-specific insights

    View All

    Agios Announces Topline Results from RISE UP Phase 3 Trial of Mitapivat in Sickle Cell Disease

    Trial met primary endpoint of hemoglobin response and key secondary endpoints of change from baseline in hemoglobin concentration and indirect bilirubin Trial showed trend favoring mitapivat but did not meet statistical significance in primary endpoint of annualized rate of SCPCs (pain crises), and the key secondary endpoint of change from baseline in PROMIS Fatigue was not met Patients in the mitapivat arm who achieved hemoglobin response had clinically meaningful benefits in SCPC-related endpoints and PROMIS Fatigue Favorable safety profile observed in RISE UP Phase 3 trial was consistent with that observed in prior mitapivat sickle cell disease trials Company will share the comprehens

    11/19/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

    $12.9 million in third quarter PYRUKYND® (mitapivat) net revenuesPDUFA goal date for PYRUKYND U.S. sNDA in thalassemia set for December 7, 2025CHMP adopted positive opinion for PYRUKYND in thalassemia; EC decision expected by early 2026RISE UP Phase 3 trial topline results in sickle cell disease by year-end; potential U.S. commercial launch in 2026Phase 2b tebapivat trial in lower-risk MDS fully enrolled; topline results expected in early 2026$1.3 billion dollars in cash, cash equivalents and marketable securities as of September 30, 2025 CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused

    10/30/25 6:30:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

    CAMBRIDGE, Mass., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter 2025 financial results and business highlights. The live webcast will be accessible on the Investors section of the company's website (www.agios.com) under the "Events & Presentations" tab. A replay of the webcast will be available on the company's website approximately two hours after the event. About Agios: Fueled by Connections

    10/16/25 7:00:00 AM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AGIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/14/24 3:44:53 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc.

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    11/8/24 2:40:47 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Agios Pharmaceuticals Inc. (Amendment)

    SC 13G/A - AGIOS PHARMACEUTICALS, INC. (0001439222) (Subject)

    2/14/24 2:21:13 PM ET
    $AGIO
    Biotechnology: Pharmaceutical Preparations
    Health Care